Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-01610 | Tisotumab vedotin | 1418731-10-8 |
| Tisotumab vedotin is an antibody-drug conjugate comprising a fully human monoclonal antibody specific for tissue factor (TF-011) conjugated to monomethyl auristatin E (MMAE). Tisotumab vedotin has been approved for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. | Inquiry | |
| BADC-01611 | Farletuzumab ecteribulin | 2407465-18-1 |
| Farletuzumab ecteribulin is an antibody-drug conjugate consisting of the humanized antifolate receptor-alpha (FRα) monoclonal antibody conjugated to eribulin by a cathepsin B-cleavable linker. | Inquiry | |
| BADC-01612 | Moxetumomab pasudotox | 1020748-57-5 |
| Moxetumomab pasudotox is a recombinant immunotoxin composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38-kDa fragment of Pseudomonas exotoxin A, called PE38. Moxetumomab pasudotox has been used in the study of acute lymphoblastic leukemia (ALL). | Inquiry | |
| BADC-01613 | Zilovertamab vedotin | |
| Zilovertamab vedotin is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) targeting antibody-drug conjugate consisting of zilovertamab, a proteolytically cleavable linker, and the antimicrotubule agent monomethyl auristatin E. | Inquiry | |
| BADC-01614 | Glembatumumab vedotin | 1182215-65-1 |
| Glembatumumab vedotin is an antibody-drug conjugate consisting of a fully human IgG2 monoclonal antibody (CR011) against gpNMB conjugated to the microtubule inhibitor, monomethyl auristatin E (MMAE). Glembatumumab vedotin exhibits anticancer activity. | Inquiry | |
| BADC-01615 | Trastuzumab duocarmazine | 1642152-40-6 |
| Trastuzumab duocarmazine is a HER2-targeting antibody-drug conjugate comprised of trastuzumab bound to a linker drug containing duocarmycin. Trastuzumab duocarmazine has been used in the research of HER2-positive locally advanced or metastatic breast cancer therary. | Inquiry | |
| BADC-01616 | Cantuzumab ravtansine | 868747-45-9 |
| Cantuzumab ravtansine is an antibody-drug conjugate comprised of a humanized monoclonal antibody cantuzumab (huC242) linked to a cytotoxic agent, ravtansine (DM4). | Inquiry | |
| BADC-02000 | Indatuximab ravtansine | 1238517-16-2 |
| Indatuximab ravtansine is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells. | Inquiry | |
| BADC-02001 | Oportuzumab monatox | 945228-48-8 |
| Oportuzumab monatox is a recombinant fusion protein consists of a monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A. Oportuzumab monatox is developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). | Inquiry | |
| BADC-02002 | Lorvotuzumab mertansine | 1008106-64-6 |
| Lorvotuzumab mertansine is an ADC consists of a CD56-targeting antibody conjugated with an antimitotic agent. Lorvotuzumab mertansine is designed for the treatment of CD56-expressing cancers. | Inquiry | |
| BADC-02020 | DEDN6526A | |
| DEDN6526A is an antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody against anti-endothelin B receptor (ETBR) and the tubulin inhibitor monomethyl auristatin E (MMAE). DEDN6526A was developed for the treatment of Metastatic or Unresectable Melanoma. | Inquiry | |
| BADC-02029 | ADCT-901 | |
| ADCT-901 is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody (3A4) directed against human KAAG1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD-dimer cytotoxin. KAAG1 is highly and selectively expressed on tumor cell surface. | Inquiry | |
| BADC-02030 | Mirvetuximab-MMAE | |
| Mirvetuximab-MMAE is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against FOLR1 and the tubulin inhibitor monomethyl auristatin E (MMAE). Mirvetuximab-MMAE can be used in the research of FRα-positive cancers. | Inquiry | |
| BADC-02031 | Codrituzumab-MMAE | |
| Codrituzumab-MMAE is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against GPC3 (glypican-3) and the tubulin inhibitor monomethyl auristatin E (MMAE). Codrituzumab could induce antibody-dependent cellular cytotoxicity (ADCC) and inhibit tumor growth. | Inquiry | |
| BADC-02032 | Ags-16C3F | |
| Ags-16C3F is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against ENPP3/CD203c and the microtubule inhibitor monomethyl auristatin F (MMAF). Ags-16C3F is under investigation for the treatment of metastatic renal cell carcinoma. | Inquiry |
